Product information

From Health Canada

New search

The product monograph is developed by a drug sponsor according to guidelines published by Health Canada that provide direction on the content and format. The veterinary labelling is developed by the drug sponsor according to the Food and Drug Regulations. While Health Canada reviews the product monograph or the veterinary labelling as part of the drug review process, it remains the responsibility of the drug sponsor to ensure that the product monograph or the veterinary labelling is complete and accurate.

Current status:

Approved

Current status date:

2021-06-29

Product name:

ABRILADA

Help on accessing alternative formats, such as Portable Document Format (PDF), Microsoft Word and PowerPoint (PPT) files, can be obtained in the alternate format help section .

DIN:

02511061

Product Monograph/Veterinary Labelling:

Date: 2021-04-09 Product monograph/Veterinary Labelling (PDF version ~ 175K)

Company: 

PFIZER CANADA ULC
17300 Trans-Canada Highway
Kirkland
Quebec
Canada  H9J 2M5

Class: 

Human

Dosage form(s):

Solution

Route(s) of administration:

Subcutaneous

Number of active ingredient(s):

1

Schedule(s):

Prescription,  Schedule D  

Biosimilar Biologic Drug:

Yes

American Hospital Formulary Service (AHFS): See footnote 3

92:36.00   DISEASE-MODIFYING ANTIRHEUMATIC AGENTS

Anatomical Therapeutic Chemical (ATC): See footnote 4

L04AB04  ADALIMUMAB

Active ingredient group (AIG) number:See footnote 5

0150364003

List of active ingredient(s)
Active ingredient(s) Strength
ADALIMUMAB 20 MG / 0.4 ML

Application information

Related information

Contact us

Version 3.9.1
Date modified: